these patients must meet the diagnostic criteria of both diseases with documented cognitive decline for at least 6 months. Clinical suspicion must be aided by cognitive scales, neuropsychology testing, laboratory tests, and anatomic imaging with CT or MRI [3] . Although the U.S. Food and Drug Administration has approved three amyloid imaging agents ( 18 F-florbetapir, 18 F-flutemetamol, and 18 F-florbetaben) and their utility has been described in characterizing early AD and several other dementia subtypes, amyloid PET is not reimbursed by CMS [4] . However, the use of metabolic and amyloid imaging for both atypical and typical causes of dementia continues to evolve in both the research and clinical arenas. Given the considerable clinical overlap with the more common dementias, familiarity with the imaging appearances of atypical dementias is necessary.
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The purpose of this article is to build on the reader's knowledge of the classic anatomic and metabolic appearances of the more common degenerative dementias and apply those same principles to the uncommon-but clinically important-subset of atypical degenerative dementias.
Imaging Techniques
Standardized imaging protocols for both anatomic and metabolic imaging of the brain are essential for reliable and accurate diagnoMultimodality Imaging of Neurodegenerative Processes: Part 2, Atypical Dementias P rogress in anatomic and metabolic imaging, as described in part 1 [1] , has led to a multimodality approach for imaging patients with cognitive decline. Although the combination of Alzheimer disease (AD), frontotemporal dementia (FTD), vascular dementia, and dementia with Lewy bodies (DLB), which are discussed in part 1 [1] , accounts for at least 85% of the degenerative dementias, the remainder is significant. These atypical degenerative dementias have varied clinical presentations, prognoses, and treatments. As a result, correct diagnosis is essential for proper patient care and education.
The major international radiology societies have recognized the importance of multimodality imaging in these atypical cases. The current American College of Radiology Appropriateness Criteria for dementia and movement disorders recommends advanced anatomic imaging in all patients while reserving FDG and amyloid PET/CT for problem-solving purposes, such as those commonly encountered in atypical degenerative dementias [2, 3] . Nevertheless, the Centers for Medicare & Medicaid Services (CMS) currently reimburses for only a single technically adequate FDG PET/CT examination of patients with presumed, probable, or uncertain AD when an alternate diagnosis of FTD is being considered. More specifically, OBJECTIVE. The purpose of this article is to describe the role of multimodality imaging in the evaluation of atypical neurodegenerative conditions. An imaging approach to the more common dementia disease processes was described in part 1. This article, part 2, briefly discusses current Centers for Medicare & Medicaid Services coverage for imaging patients with dementia and illustrates the basic concepts of combining anatomic, metabolic, and amyloid imaging in the evaluation of patients with atypical neurodegenerative dementia. Although these disease processes are rare, the growing repertoire of clinically available imaging techniques necessitates an understanding of their imaging patterns.
CONCLUSION. Despite the rarity of these conditions, imaging of patients with neurodegenerative disorders is on the rise, and familiarity with the imaging appearances of these atypical causes is increasingly important.
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sis of degenerative dementias and for longitudinal studies evaluating disease progression in both the clinical and research realms. Protocols for anatomic and metabolic imaging with MRI and PET/CT were described in part 1 [1] . To summarize briefly, detailed anatomic imaging with MRI is preferable to CT because of MRI's increased sensitivity. Traditional MRI sequences including sagittal T1-weighted, axial T2-weighted, axial FLAIR, and DWI sequences should be considered the bare minimum for an adequate evaluation. These sequences are frequently augmented by a 3D volumetric T1-weighted acquisition to give a more accurate qualitative or quantitative measurement of focal atrophy [5] . Gradient-recalled echo or susceptibility-weighted images along with gadolinium-enhanced images are also frequently used.
Metabolic imaging with 18 F-FDG (FDG) PET/CT remains the main staple of metabolic imaging. Dedicated brain acquisition, as described in part 1 [1] , can provide a reliable and reproducible means to measure cortical glucose metabolism, which is essential in characterizing degenerative dementias [6] . The addition of a semiquantitative analysis is a relatively simple way to significantly increase both sensitivity and specificity [7] and at our institution is considered the standard of care both by the interpreting physician and by the referring clinicians. Quantitative programs sample the FDG PET dataset at thousands of cortical locations to create a 3D stereotactic surface projection (SSP). An age-matched Zscore can be generated for each cortical region by comparing with a normative database on a voxel-by-voxel basis. The Z-score data can then be displayed on 3D SSP brain surface maps for visual inspection [8] .
Amyloid PET/CT has gained an increasing role for clinical evaluation of degenerative dementias. The current appropriate use criteria from the Amyloid Imaging Taskforce, a joint effort of the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging, states that amyloid PET should be considered in patients when there is significant diagnostic uncertainty after comprehensive evaluation and when the results are anticipated to increase diagnostic certainty and alter management [9, 10] .
Atypical Degenerative Dementias
The atypical degenerative dementias are an unusual collection of disease processes that are typically more aggressive than the disorders discussed in part 1 [1] . The initial clinical presentation of atypical degenerative dementias can often be confusing, and both prognostication and symptomatic management can be greatly aided by accurate diagnosis with the help of anatomic and metabolic imaging (Table 1) .
Corticobasal Degeneration
Corticobasal degeneration (CBD) is characterized by cognitive decline or behavioral disturbance that precedes the development of a movement disorder, typically asymmetric parkinsonism or alien limb phenomenon [11] [12] [13] [14] . Specific cognitive features include executive dysfunction, aphasia, apraxia, and visuospatial disturbances. Similar to the parkinsonism of many other atypical degener- Note-Downward-pointing arrow (↓) = decreased metabolism, MSA-P = multiple-system atrophy with predominantly parkinsonism symptoms, MSA-C = multiple-system atrophy with predominantly cerebellar ataxia symptoms, upward-pointing arrow (↑) = increased metabolism.
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ative dementias, parkinsonism in CBD can be differentiated from idiopathic Parkinson disease in that it is typically asymmetric and lacks a robust response to levodopa therapy [15] . Current research suggests that CBD may be further divided into FTD and AD subtypes on the basis of the underlying histology at autopsy [12] . Although not robust, dopaminergic drugs may be helpful for symptom treatment. Targeted therapy with botulinum toxin for symptomatic limb dystonia can also improve quality of life [16] . A relatively aggressive course is typically seen, with a mean survival of 8 years from symptom onset [14] . Anatomic imaging-In the early stages of CBD, the MRI findings may be subtle. With disease progression, asymmetric cortical atrophy involving the frontoparietal lobes and corpus callosum may be present (Fig. 1A ). There may also be atrophy of the ipsilateral cerebellar peduncle. On T2-weighted sequences, marked hypointensity can be seen in the putamen and globus pallidum. Volume loss does not occur in the basal ganglia and hippocampi, which can be helpful in differentiation from AD [17] [18] [19] .
Metabolic imaging-FDG PET/CT classically shows asymmetric basal ganglia and cortical hypometabolism contralateral to the patient's affected side (Figs. 1B-1D ). Frequently this is manifested by left-sided cerebral hypometabolism in the context of rightsided symptoms [20, 21] . The parietal and, to a lesser extent, frontal lobes are frequently involved early in the disease process. Interestingly, studies have revealed hypermetabolism in the basal ganglia and cortex ipsilateral to the clinically affected side [21] .
Amyloid imaging-The AD subtype of CBD theoretically may show a pattern of amyloid deposition similar to that of AD. However, the prevalence of amyloid-positive CBD is not yet known [12] .
Multiple-System Atrophy
Like CBD, multiple-system atrophy (MSA) is a neurodegenerative movement disorder characterized by prominent parkinsonism. Cognitive decline and cerebellar ataxia with early falls are characteristic of this disorder. When dysautonomia predominates, this condition may be termed "ShyDrager syndrome." This disease process is further subclassified on the basis of the type of movement disorder: MSA with predominantly parkinsonism symptoms is referred to as "MSA-P," and MSA with predominantly cerebellar ataxia symptoms is referred to as "MSA-C" [22] . Dopamine replacement therapy is not beneficial in patients with MSA, unlike patients with CBD, and can potentially aggravate the dysautonomia. As with the other atypical degenerative dementias, the clinical course of MSA is aggressive, and death typically occurs within 10 years of diagnosis. In patients with prominent dysautonomia, the prognosis can be even worse.
Anatomic imaging-Multiple distinct patterns may be seen on conventional MRI of patients with MSA. In MSA-P, putaminal abnormalities predominate with atrophy and symmetric hypointensity on T2-weighted and gradient-weighted images [22] . Nevertheless, this putaminal T2 hypointensity is nonspecific and may also be seen with progressive supranuclear palsy (PSP), Wilson disease, iron deposition, and other acquired conditions [23] . A slitlike T2 marginal hyperintensity may also be seen in the putamen; however, this finding has also been identified in healthy patients studied with 3-T magnets [24] . In patients with MSA-C, atrophy of the inferior basis pontis, medulla, middle cerebellar peduncles, and cerebellar hemispheres with associated widening of the fourth ventricle may be seen [23] . These patients may show the classic triad cruciform T2 signal in the pons termed the "hot cross bun" sign. This sign represents focal loss of pontine neurons and transverse pontocerebellar fibers [25] (Fig. 2A) . In combination, these structural findings are relatively specific for the subtypes of MSA, but detection of these findings on imaging in early disease is suboptimal.
Metabolic imaging-FDG PET/CT may reveal striatal, brainstem, and cerebellar hypometabolic patterns that mirror the regions of structural atrophy and T2 signal abnormalities on MRI. Specifically, patients with MSA-P may show putaminal hypometabolism, and patients with MSA-C may show cerebellar and middle cerebellar peduncle hypometabolism [20] (Figs. 2B-2D ). However, patients with MSA-P without cerebellar symptoms may also have cerebellar hypometabolism [26] .
Amyloid imaging-Patients with MSA show no amyloid deposition on amyloid PET.
Progressive Supranuclear Palsy
PSP is clinically characterized by parkinsonism, postural instability, and vertical gaze palsy. PSP is the second most common cause of parkinsonism after idiopathic Parkinson disease. PSP is characterized by early falls within the first year of disease onset, and there is typically symmetric involvement at presentation with central (i.e., trunk and neck) involvement greater than limb involvement. Although supranuclear ophthalmoplegia is the most striking cranial nerve finding, other cranial nerves can also be involved, producing pseudobulbar palsy and cervical dystonia [27] . Concomitant cognitive impairment is typically characterized by personality change, memory impairment, and depression or apathy [22, 28] . Disease progression is usually aggressive, with death occurring within 6-10 years of diagnosis. Misdiagnosis as idiopathic Parkinson disease is not rare, and this misdiagnosis may lead to unnecessary trials of dopamine replacement therapy, to which PSP is typically unresponsive.
Anatomic imaging-Three abnormalities have been classically described in PSP on conventional MRI. These abnormalities include the following: first, atrophy of the midbrain tegmentum with relative preservation of the pons, which is termed the "hummingbird" sign, on midline sagittal images [29] ; second, atrophy of the midbrain, preservation of the tectum, and widening of the interpeduncular cistern, which is termed the "Mickey Mouse" sign, on axial images [30] ; and putaminal T2 hypointensity, which is likely caused by iron deposition [31] (Fig. 3A) . Additional findings that may assist in differentiating PSP from other neurodegenerative processes include atrophy and abnormal FLAIR signal intensity of the cerebellar peduncles [32] .
Metabolic imaging-FDG PET/CT may reveal posterior frontal cortex, midbrain, and basal ganglia hypometabolism [20, 26, 28] (Figs. 3B-3D) . A predilection for involvement of the midline structures may be seen, particularly the parasagittal frontal lobes [27] . Like hypometabolism seen in patients with AD, hypometabolism in patients with PSP typically spares the motor and sensory cortex until late in the disease process.
Amyloid imaging-PSP is characterized by accumulation of phosphorylated tau protein in the brain. No amyloid deposition has been shown on amyloid PET in the setting of PSP.
Pseudodementia
Pseudodementia has been described as a reversible dementia syndrome secondary to a primary psychiatric disorder, classically major depressive disorder. This diagnosis should be considered in the differential diagnosis of any patient with a long-standing psychiatric history. Clinically, the only major differentiating factor is the complete reversibility of the symptoms after treatment. In the popula-tion with treatment-resistant major depressive disorder, cognitive symptom improvement may be achieved only after electroconvulsive therapy (ECT) [33] . Significant morbidity and mortality can be associated with this condition, which stresses the importance of early and accurate diagnosis.
Anatomic imaging-No structural or morphologic abnormalities are seen on conventional MRI in pseudodementia. However, this lack of structural abnormalities may be indistinguishable from other early-stage dementia processes.
Metabolic imaging-A broad spectrum of presentations may be seen on FDG PET/CT; most commonly, FDG PET/CT of these patients will show normal metabolism (Fig. 4) . However, diffuse hypometabolism has also been described [34] , and there have been several cases reported of severe depressive pseudodementia with diffuse cerebral hypometabolism showing varying degrees of metabolic change after ECT. Findings include immediate progression of hypometabolism, complete resolution [35] , and minimal change despite clinical improvement [36] after ECT. The overlapping appearance of pseudodementia with that of neurodegenerative disease on FDG PET/CT has the potential to lead to misinterpretation in the setting of depression [35] . This possibility should be kept in mind when interpreting FDG PET/CT studies of patients with a significant psychiatric history.
Amyloid imaging-No amyloid deposition has been detected on amyloid PET in the setting of pseudodementia.
Paraneoplastic Neurological Syndromes
Paraneoplastic neurological syndromes (PNS) are a rare group of disorders that result from neuronal dysfunction in the setting of malignancy that is likely because of immunemediated direct damage rather than because of metastasis, infection, metabolic deficits, or treatment [37] . This phenomenon is most frequently encountered in breast, lung, and ovarian cancer and is estimated to occur in less than 0.01% of patients with cancer [38] . Most often, the symptoms of PNS develop before the detection of the primary malignancy [38] . There are multiple syndromes included in the PNS that may present clinically with cognitive symptoms; two of the more common entities include paraneoplastic limbic encephalitis and subacute cerebellar degeneration [39] . Patients with paraneoplastic limbic encephalitis, the most common clinical paraneoplastic syndrome, present with cognitive decline, confusion, and possibly seizures. Patients with subacute cerebellar degeneration typically present with profound axial and appendicular ataxia, dysarthria, and nystagmus. Accurate diagnosis can help to initiate treatment with immunemodulating therapies and elicit a search for occult malignancy in these patients.
Anatomic imaging-Conventional MRI findings may range from grossly normal to abnormal in PNS. Paraneoplastic limbic encephalitis can mimic herpes encephalitis on imaging with relatively symmetric T2 hyperintensity in the medial temporal lobes. The cingulate gyrus, insula, inferior frontal cortex, and white matter may be involved as well [40] . Minimal mass effect and patchy contrast enhancement can be present, which may confuse the imaging appearance (Fig. 5A ). In acute cases in which herpes cannot be excluded, treatment with antiviral agents is advised until herpes encephalitis can be excluded by spinal fluid examination. In paraneoplastic cerebellar degeneration, focal atrophy of the cerebellum is noted. This disorder can be difficult to accurately diagnose in patients with more widespread cerebral atrophy, but there is progressive volume loss on serial examinations [41] . The cerebellar atrophy is often more obvious on sagittal images than on axial images.
Metabolic imaging-Several patterns of altered cerebral metabolism have been described in PNS. In a recent study, investigators reported that approximately 63% of patients with PNS will show some degree of abnormality on FDG PET/CT [37] . In paraneoplastic limbic encephalitis, increased glucose metabolism is typically seen in the active phases of the disease, and glucose metabolism may be useful in monitoring response to treatment (Figs. 5B-5D ). In paraneoplastic cerebellar degeneration, marked cerebellar hypometabolism and less commonly hypermetabolism have been noted. This metabolic abnormality is often more pronounced and, expecially with quantitation, is easier to detect than cerebellar atrophy. Following treatment of the underlying malignancy, cerebral hypometabolism often develops in the involved areas in hypermetabolism that was previously present [37] .
Amyloid imaging-No amyloid deposition has been shown on amyloid PET in the setting of PNS.
Creutzfeldt-Jakob Disease
Creutzfeldt-Jakob disease (CJD) is a rare fatal prion neurodegenerative disease characterized by rapidly progressive dementia with myoclonus. Although there are classic pathologic findings on brain biopsy, noninvasive diagnosis by a combination of electroencephalography (EEG) and imaging findings is optimal to reduce the potential for additional potential prion exposures. In addition to characteristic EEG periodic complexes, highly specific features can be seen on imaging that allow accurate diagnosis of CJD [42] .
Anatomic imaging-The most common imaging finding is rapidly progressive atrophy that typically involves the frontal, temporal, and parietal lobes. Rarer subtypes can preferentially involve the occipital (Heidenhain variant) and cerebellar (OppenheimerBrownell variant) hemispheres [43, 44] . Aside from the progressive atrophy (Figs. 6A and 6B), more specific MRI features can be present and include, first, T2 signal and diffusion restriction in the pulvinar of the thalami; and, second, symmetric increased signal intensity in the pulvinar and dorsomedial thalamus that gives a "hockey stick" configuration [45] . Other findings frequently encountered include patchy gyriform T2 hyperintensity in the cerebral cortex and increased T1 signal in the globus pallidum [42] (Figs. 6C-6E) .
Molecular imaging-Although a classic appearance of CJD has not been described on FDG PET/CT, cases of regional hypometabolism in patients with CJD have been reported that could easily lead to misdiagnosis of CJD as CBD or DLB. In these cases, the rapid progression of the clinical and imaging findings ultimately led to the diagnosis of CJD [46] .
Amyloid imaging-No amyloid deposition has been shown on amyloid PET in the setting of CJD.
Huntington Disease
Huntington disease (HD) is an uncommon autosomal-dominant neurodegenerative disease with both juvenile and adult-onset forms that is characterized by cytosine-adenosineguanine trinucleotide repeats in the short arm of chromosome 4 [47, 48] . The classic adultonset form, accounting for approximately 90-95% of HD cases, typically presents in patients 40-50 years old with rapidly progressive mental deterioration and choreoathetoid movements [49] . The less common juvenile form typically presents in patients younger than 20 years old, and affected patients can have prominent rigidity [47] . Although HD is autosomal-dominant, approximately 10-15% of cases are sporadic, which can potentially lead to a delayed diagnosis [50] .
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Anatomic imaging-The main feature of HD is caudate atrophy with overall decreased size, loss of the convex medial margin of the caudate heads, and an increased intercaudate distance (Figs. 7A and 7B ). Putaminal and globus pallidus volume loss with compensatory enlargement of the anterior horns of the lateral ventricles may also be seen. The basal ganglia atrophy can be subtle, especially in minimally symptomatic patients or in presymptomatic patients [51] . Therefore, volumetric quantitation may be useful. Nonspecific T2 hypointensity in the striatum can result from iron deposition. In the juvenile form, T2 hyperintensity in the caudate and putamen may occur due to gliosis [47, 48, 52] .
Molecular imaging-FDG PET typically shows hypometabolism in the frontal and temporal lobes and more severe deficits in the basal ganglia (Figs. 7C and 7D ). These metabolic abnormalities can be identified in patients with HD many years before the onset of clinical symptoms [53, 54] . Some sources suggest that decreased cortical glucose metabolism is a predictor for more rapid HD progression [55, 56] . Imaging with less common PET radiotracers such as 11 C-raclopride, a D2 dopamine antagonist, can detect even subtler alterations in basal ganglia function and may be used to prognosticate disease severity and correlate with the number of trinucleotide repeats [57] (Figs 7E and 7F) .
Amyloid imaging-No amyloid deposition has been reported on amyloid PET in the setting of HD.
Conclusion
In part 1 [1] , we discussed multimodality imaging of the most common neurodegenerative causes of dementia. In part 2, we build on the reader's knowledge by describing less common causes of degenerative dementia and illustrate the complementary roles of anatomic, metabolic, and sometimes amyloid imaging. Despite the rarity of these conditions, imaging of patients with neurodegenerative disorders is on the rise, and familiarity with the imaging appearances of these atypical causes is increasingly important. 
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